SOP Status epilepticus bei Erwachsenen

Der Status epilepticus ist ein häufiger neurologischer Notfall. Trotz erheblicher Fortschritte in der Notfall- und Intensivmedizin in den letzten Jahren ist der Status epilepticus weiterhin mit einer hohen Mortalität assoziiert. Wichtige Faktoren für die erfolgreiche Status-epilepticus-Therapie ist neben der Kenntnis und Umsetzung von leitliniengerechten Therapiealgorithmen vor allem die ausreichend hoch dosierte Benzodiazepingabe in der Initialphase.

Abstract

Status epilepticus is a common neurological emergency. Despite significant advances in emergency and intensive care medicine in recent years, status epilepticus continues to be associated with high mortality. In addition to knowledge and implementation of guideline-based treatment algorithms, an important factor for successful treatment of status epilepticus is, above all, the administration adequately high dose of benzodiazepines in the initial phase.

Schlüsselwörter

Epilepsie - Notfallmedizin - Benzodiazepin - neurologischer Notfall

Keywords

epilepsy - emergency medicine - benzodiazepine - neurological emergency

Publication History

Article published online:
10 December 2025

• Literatur

• 1 Leitinger M, Trinka E, Giovannini G. et al. Epidemiology of status epilepticus in adults: a population-based study on incidence, causes, and outcomes. Epilepsia 2019; 60: 53-62
• 2 Neligan A, Noyce AJ, Gosavi TD. et al. Change in mortality of generalized convulsive status epilepticus in high-income countries over time: a systematic review and meta-analysis. JAMA Neurol 2019; 76: 897-905
• 3 Rosenow F, Weber J. et al. Status epilepticus im Erwachsenenalter, S2k-Leitlinie. Leitlinien für Diagnostik und Therapie in der Neurologie. 2020 Accessed August 06, 2025 at: https://www.dgn.org/leitlinien
• 4 Jungilligens J, Michaelis R, Popkirov S. Misdiagnosis of prolonged psychogenic non-epileptic seizures as status epilepticus: epidemiology and associated risks. J Neurol Neurosurg Psychiatry 2021; 92: 1341-1345
• 5 Bauer G, Trinka E. Nonconvulsive status epilepticus and coma. Epilepsia 2010; 51: 177-190
• 6 Leitinger M, Beniczky S, Rohracher A. et al. Salzburg consensus criteria for non-convulsive status epilepticus – approach to clinical application. Epilepsy Behav 2015; 49: 158-163
• 7 DeLorenzo RJ, Waterhouse EJ, Towne AR. et al. Persistent nonconvulsive status epilepticus after the control of convulsive status epilepticus. Epilepsia 1998; 39: 833-840
• 8 Kellinghaus C, Rossetti AO, Trinka E. et al. Factors predicting cessation of status epilepticus in clinical practice: data from a prospective observational registry (SENSE). Ann Neurol 2019; 85: 421-432
• 9 Silbergleit R, Durkalski V, Lowenstein D. et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med 2012; 366: 591-600
• 10 Kay L, Merkel N, von Blomberg A. et al. Intranasal midazolam as first-line inhospital treatment for status epilepticus: a pharmaco-EEG cohort study. Ann Clin Transl Neurol 2019; 6: 2413-2425
• 11 Kapur J, Elm J, Chamberlain JM. et al. Randomized trial of three anticonvulsant medications for status epilepticus. N Engl J Med 2019; 381: 2103-2113
• 12 Hawkes MA, Eliliwi M, Wijdicks EFM. The origin of the burst-suppression paradigm in treatment of status epilepticus. Neurocrit Care 2024; 40: 849-854
• 13 Musialowicz T, Mervaala E, Kalviainen R. et al. Can BIS monitoring be used to assess the depth of propofol anesthesia in the treatment of refractory status epilepticus?. Epilepsia 2010; 51: 1580-1586
• 14 Muhlhofer WG, Layfield S, Lowenstein D. et al. Duration of therapeutic coma and outcome of refractory status epilepticus. Epilepsia 2019; 60: 921-934
• 15 Bellante F, Legros B, Depondt C. et al. Midazolam and thiopental for the treatment of refractory status epilepticus: a retrospective comparison of efficacy and safety. J Neurol 2016; 263: 799-806
• 16 Rossetti AO, Milligan TA, Vulliemoz S. et al. A randomized trial for the treatment of refractory status epilepticus. Neurocrit Care 2011; 14: 4-10
• 17 Claassen J, Taccone FS, Horn P. et al. Recommendations on the use of EEG monitoring in critically ill patients: consensus statement from the neurointensive care section of the ESICM. Intensive Care Med 2013; 39: 1337-1351
• 18 Delaj L, Novy J, Ryvlin P. et al. Refractory and super-refractory status epilepticus in adults: a 9-year cohort study. Acta Neurol Scand 2017; 135: 92-99
• 19 Thakur KT, Probasco JC, Hocker SE. et al. Ketogenic diet for adults in super-refractory status epilepticus. Neurology 2014; 82: 665-670
• 20 Cervenka MC, Hocker S, Koenig M. et al. Phase I/II multicenter ketogenic diet study for adult superrefractory status epilepticus. Neurology 2017; 88: 938-943
• 21 Gaspard N, Foreman B, Judd LM. et al. Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study. Epilepsia 2013; 54: 1498-1503
• 22 Hofler J, Rohracher A, Kalss G. et al. (S)-Ketamine in refractory and super-refractory status epilepticus: a retrospective study. CNS Drugs 2016; 30: 869-876
• 23 Stetefeld HR, Schaal A, Scheibe F. et al. Isoflurane in (super-) refractory status epilepticus: a multicenter evaluation. Neurocrit Care 2021; 35: 631-639
• 24 Legriel S, Lemiale V, Schenck M. et al. Hypothermia for neuroprotection in convulsive status epilepticus. N Engl J Med 2016; 375: 2457-2467